HIV Testing and Baseline Evaluation Strategies
Initial Screening Approach
Use a fourth-generation HIV-1/2 antigen/antibody immunoassay as the initial screening test, which can detect infection as early as 14 days post-exposure by identifying both p24 antigen and IgM/IgG antibodies 1, 2. This represents a significant improvement over third-generation antibody-only tests and is now the standard of care.
Fourth-Generation Testing Algorithm
When the initial fourth-generation immunoassay is reactive:
- Immediately perform repeat testing in duplicate on the same specimen 3
- If repeatedly reactive, proceed directly to HIV-1/HIV-2 antibody differentiation assay (such as Multispot or INNO-LIA) 4, 3
- The Western blot is no longer recommended for confirmation per current CDC guidelines 4
Critical Addition: RNA PCR Testing
If the fourth-generation test is reactive but the differentiation assay is negative or indeterminate, immediately perform HIV-1 RNA nucleic acid testing (NAT) 4, 3. This step is essential because:
- It identifies acute HIV infection during the window period when antibodies have not yet developed 3, 5
- In one study, this algorithm detected 2 acute infections that would have been missed by antibody testing alone 3
- RNA testing can detect infection approximately 10-14 days earlier than fourth-generation tests 2
When to Include RNA Testing at Baseline
For PrEP initiation or high-risk presentations, include HIV-1 RNA testing alongside the fourth-generation antigen/antibody test at baseline 6. This dual approach is particularly important when:
- Symptoms suggest acute retroviral syndrome (fever, lymphadenopathy, rash, pharyngitis) 7, 8
- Recent high-risk exposure within the past 2-4 weeks
- Patient is initiating or resuming PrEP 6
- If RNA testing is unavailable at PrEP initiation, repeat antigen/antibody testing at 1 month 6
Baseline Laboratory Evaluation
Once HIV infection is confirmed, obtain the following baseline labs:
Essential Initial Labs
- CD4+ T-cell count and percentage - establishes disease stage and guides prophylaxis decisions
- HIV-1 RNA viral load - baseline for monitoring treatment response
- HIV genotype resistance testing - perform before initiating antiretroviral therapy
- Complete blood count with differential
- Comprehensive metabolic panel (renal and hepatic function)
- Fasting lipid panel and glucose
- Hepatitis A, B, and C serologies
- Syphilis screening (treponemal test preferred over RPR alone, as RPR showed only 49.4% positive predictive value in one study) 9
- Toxoplasma IgG
- Tuberculosis testing (interferon-gamma release assay or tuberculin skin test)
- Pregnancy test for individuals of childbearing potential
Follow-Up Monitoring Strategy
For Patients on Antiretroviral Therapy
- HIV-1 RNA viral load: at 2-4 weeks after initiation, then every 4-8 weeks until undetectable, then every 3-6 months
- CD4+ count: every 3-6 months initially, can extend to annually once consistently >300-500 cells/μL and virologically suppressed
- Resistance testing: if virologic failure occurs (confirmed viral load >200 copies/mL)
For PrEP Monitoring
- HIV testing every 3 months using fourth-generation antigen/antibody test 6
- For long-acting cabotegravir PrEP: use rapid HIV antibody test plus laboratory-based antigen/antibody test; routine RNA testing is not recommended 6
- STI screening quarterly at all exposure sites 6
- Renal function monitoring (creatinine) every 6 months for tenofovir-based regimens
Special Populations and Timing Considerations
Pregnant Individuals
- Test as early as possible in pregnancy with opt-out screening 7
- Repeat testing in third trimester (preferably <36 weeks) for those in high-prevalence areas or with ongoing risk factors 7
- Rapid testing during labor for anyone with undocumented status 7
- If maternal status unknown postpartum, test newborn immediately to enable antiretroviral prophylaxis within 12 hours of birth 7
Acute Presentation Scenarios
When acute HIV is suspected clinically (fever, lymphadenopathy, pharyngitis in high-risk individual):
- Do not rely on antibody tests alone - they may be negative during acute infection 8
- Perform HIV-1 RNA PCR immediately alongside fourth-generation testing 7, 8
- One case report documented a patient with negative fourth-generation test one month prior who presented with strep pharyngitis but had HIV RNA >3.6 million copies/mL 8
Common Pitfalls to Avoid
Never assume a negative test from 2-4 weeks ago rules out HIV in symptomatic patients - acute infection can present with non-specific symptoms easily attributed to other diagnoses 8
Do not use third-generation antibody-only tests - they miss the critical window period where fourth-generation tests are positive 5
Isolated gp41 reactivity on differentiation assays (particularly INNO-LIA) frequently causes indeterminate results but is usually false-positive when RNA is negative 9, 10. The recomLine assay produces fewer indeterminate results (2.8% vs 13.3%) 10
Do not delay treatment decisions waiting for confirmatory results in pregnant individuals - initiate prophylaxis based on reactive screening test 7
Maintain high suspicion even with concurrent diagnoses - the case of confirmed strep pharyngitis with concurrent acute HIV demonstrates that multiple diagnoses can coexist 8
Laboratory Turnaround Time
The modern algorithm significantly improves reporting speed: 96% of concordant reactive results can be reported within 2 workdays, compared to only 22% with the old Western blot algorithm 3. This rapid turnaround enables earlier linkage to care and treatment initiation, which is critical for both individual outcomes and transmission prevention.